Open AccessParadoxical relationship between proton pump inhibitors and COVID-19: A systematic review and meta-analysis
Author(s) -
Maddalena Zippi,
Sirio Fiorino,
Roberta Budriesi,
Matteo Micucci,
Ivan Corazza,
Roberta Pica,
Dario de Biase,
Claudio Gallo,
Wandong Hong
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i12.2763
Subject(s) - medicine , cochrane library , medline , meta analysis , intensive care medicine , covid-19 , systematic review , medical literature , disease , coronavirus , pathology , infectious disease (medical specialty) , political science , law
The proton pump inhibitors (PPIs), used to reduce gastric acid secretion, represent one of the most widely used pharmaceutical classes in the world. Their consumption as a risk factor for the evolution of severe forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been investigated as well as the mortality of these patients. These risks also appear to be linked to the duration and the dosage. On the other hand, several studies have emerged with regard to the protective or therapeutic effects of these drugs. More and more evidence underlines the immunomodulatory and anti-fibrotic role of PPIs. In addition, their ability to alkalize the contents of endosomes and lysosomes serves as an obstacle to the entry of the virus into the host cells.